Cell line · CVCL_0597
Papers82
1 to 20 of 82
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| SorLA regulates B cell receptor uptake, trafficking, and B cell-mediated immune responses in vivo. | J Exp Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A 3D genome atlas of human tonsil and the role of loop extrusion in B cell somatic hypermutation. | Science | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Identification of a Shiga toxin A-derived peptide internalized into Gb3 receptor-bearing cells via interaction with the Shiga toxin B subunit. | FEBS Lett | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A first-in-class bifunctional antibody targeting CD20 and CD37 remodels the immune microenvironment in relapsed or refractory B-cell malignancies. | J Hematol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The Growth Supporting Role of ZDHHC11 Is Linked to the MEF2B-BCL6 Regulatory Circuit in Burkitt Lymphoma. | Int J Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Enhancing Proteasome Activity in T Cells Alleviates Exhaustion and Improves Antitumor Immunity. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting scavenger receptor class B type 1 with a bioinspired ligand induces apoptosis or ferroptosis in AML. | Blood Neoplasia | 2025 | Its Methods give the RRID and name the line | PubMed | |
| DUSP11 is an Intracellular Innate Immune Checkpoint in Lung Adenocarcinoma. | Cancer Immunol Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| TP53 upregulation via aurora kinase inhibition overcomes primary failure to venetoclax in BCL2-rearranged lymphomas. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Assessment of the Effects of Single-Domain Anti-Idiotypic Distribution Enhancers on the Disposition of Trastuzumab and on the Efficacy of a PE24-Trastuzumab Immunotoxin. | Cancers (Basel) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Dual targeting of EZH2 and PD-L1 in Burkitt's lymphoma enhances immune activation and induces apoptotic pathway. | Front Immunol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Broadening the Therapeutic Window of ADCs Using Site-Specific Bioconjugation Showcased by an MMAE-Containing Peptide Linker in a CD79b-Targeting ADC. | Mol Cancer Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Ammonia Suppresses the Antitumor Activity of Natural Killer Cells and T Cells by Decreasing Mature Perforin. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| TCL1A in naïve B cells as a therapeutic target for type 1 diabetes. | EBioMedicine | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Encapsulation and Delivery of the Kinase Inhibitor PIK-75 by Organic Core High-Density Lipoprotein-Like Nanoparticles Targeting Scavenger Receptor Class B Type 1. | ACS Appl Mater Interfaces | 2025 | Its Methods give the RRID and name the line | PubMed | |
| B7H6 is the predominant activating ligand driving natural killer cell-mediated killing in patients with liquid tumours: evidence from clinical, in silico, in vitro, and in vivo studies. | EBioMedicine | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Preclinical Evaluation of STI-8811, a Novel Antibody-Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Biological changes in human B-cell line Ramos (RA.1) related to increasing doses of human parathyroid hormone. | Heliyon | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. | Cancer Cell | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Effects of Cannabidiol, ∆9-Tetrahydrocannabinol, and WIN 55-212-22 on the Viability of Canine and Human Non-Hodgkin Lymphoma Cell Lines. | Biomolecules | 2024 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0597/papers